Stories

Top highlights include: Genome-wide association study reveals novel genetic loci: a new polygenic risk score for mitral valve prolapse.

A pioneering researcher, Dr. Vanda Lennon has spent five decades delving into questions of neuroimmunology. Today, she continues that work as director of the Neuroimmunology Research Laboratory in Mayo Clinic’s Department of Laboratory Medicine and Pathology.

Featured abstract: An overview of the clinical presentation, pathology, and the current therapeutic approach of the main representative disorders in the spectrum of glomerulonephritis.

For a young child diagnosed with inflammatory bowel disease, an unexpected turn of events led by results of a Mayo Clinic Laboratories test freed him and his family from the bonds of frequent medical visits and expensive treatment, and opened the door to a life unencumbered by illness.

Top highlights include: Arrhythmia variant associations and reclassifications in the eMERGE-III sequencing study.

Top highlights include: Advances in neuroimaging for brain charts for the human lifespan.

In a world of ever-faster technical change, Mayo Clinic Laboratories is uniquely positioned to innovate. Collaboration with clinicians pinpoints unmet patient needs and facilitates the development of diagnostic testing that provides answers.

Before he arrived at Mayo Clinic, Tim Brantner worked for a variety of organizations outside of health care. He joined Mayo Clinic Laboratories 14 years ago to help tell the labs’ story.

Sophisticated laboratory testing solved a medical riddle and finally got Jori Pearson back on his feet, doing what he loves.

This Feature Includes: Preclinical modeling in glioblastoma patient-derived xenograft (GBM PDX) xenografts to guide clinical development of lisavanbulin-a novel tumor checkpoint controller targeting microtubules.

Topic's Include: Breakthrough hospitalizations ‘extremely uncommon’ after COVID-19 immunity, Mayo study finds, and Mayo Clinic in Rochester continues to ease visitor restrictions for hospitalized patients.

This Feature Includes: A clinically compatible drug-screening platform based on organotypic cultures identifies vulnerabilities to prevent and treat brain metastasis.

Each day, some 40 to 45 thousand specimens are shipped to Mayo Clinic Laboratories in Rochester, Minnesota, from hospitals and other health care organizations around the world. And for every sample, there’s a patient to whom it belongs, someone on the other end hoping for answers to a challenging, perhaps even life-threatening, condition.